Sexual Dysfunction Associated with the Drug Treatment of Psychiatric Disorders

Incidence and Treatment

Dan J. Stein, Eric Hollander

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Adverse sexual effects of psychiatric medication can cause considerable distress to patients and so lead to noncompliance. Despite the clinical importance of psychotropic-induced sexual dysfunction, there is relatively little systematic research on its incidence and treatment. Investigation is complicated by the fact that sexual dysfunction may predate the onset of medication or may be secondary to the presenting illness. In addition, objective measures of sexual dysfunction have been difficult to construct. Few studies have attempted to combine phenomenological and physiological measures of sexual dysfunction. Nevertheless, studies suggest that sexual dysfunction is commonly seen in association with the major classes of psychotropic medication. Disturbances of erection and ejaculation are the most frequently reported sexual adverse effects of dopamine blocking antipsychotics. Antidepressant medications often lead to sexual dysfunction, with serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors commonly resulting in anorgasmia. On the other hand, certain serotonergic agents (e.g. 5-HT1A agonists) may lead to improvement in sexual symptoms, pointing to the complexity of serotonergic mediation of sexual function. Treatment of sexual dysfunction induced by psychiatric drugs commonly involves attempting to titrate dosage, or switching from one medication to another. Certain psychotropics, such as amfebutamone (bupropion), may have few adverse sexual effects. Reversal of the dopaminergic effects of antipsychotics or the serotonergic effects of antidepressants are other strategies that may be useful. Finally, there is good evidence that adrenergic receptors mediate erection and ejaculation. As a result, there is increasing research on the efficacy of agents such as yohimbine, an α2-noradrenergic antagonist, for the treatment of sexual adverse effects

Original languageEnglish (US)
Pages (from-to)78-86
Number of pages9
JournalCNS Drugs
Volume2
Issue number1
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Psychiatry
Bupropion
Serotonin
Ejaculation
Antidepressive Agents
Antipsychotic Agents
Incidence
Physiological Sexual Dysfunctions
Pharmaceutical Preparations
Serotonin 5-HT1 Receptor Agonists
Serotonin Agents
Dopamine Agents
Yohimbine
Prednisolone
Research
Adrenergic Receptors
Dopamine
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Sexual Dysfunction Associated with the Drug Treatment of Psychiatric Disorders : Incidence and Treatment. / Stein, Dan J.; Hollander, Eric.

In: CNS Drugs, Vol. 2, No. 1, 1994, p. 78-86.

Research output: Contribution to journalArticle

@article{c5390e46d2e44df5927ae90e1f73e61b,
title = "Sexual Dysfunction Associated with the Drug Treatment of Psychiatric Disorders: Incidence and Treatment",
abstract = "Adverse sexual effects of psychiatric medication can cause considerable distress to patients and so lead to noncompliance. Despite the clinical importance of psychotropic-induced sexual dysfunction, there is relatively little systematic research on its incidence and treatment. Investigation is complicated by the fact that sexual dysfunction may predate the onset of medication or may be secondary to the presenting illness. In addition, objective measures of sexual dysfunction have been difficult to construct. Few studies have attempted to combine phenomenological and physiological measures of sexual dysfunction. Nevertheless, studies suggest that sexual dysfunction is commonly seen in association with the major classes of psychotropic medication. Disturbances of erection and ejaculation are the most frequently reported sexual adverse effects of dopamine blocking antipsychotics. Antidepressant medications often lead to sexual dysfunction, with serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors commonly resulting in anorgasmia. On the other hand, certain serotonergic agents (e.g. 5-HT1A agonists) may lead to improvement in sexual symptoms, pointing to the complexity of serotonergic mediation of sexual function. Treatment of sexual dysfunction induced by psychiatric drugs commonly involves attempting to titrate dosage, or switching from one medication to another. Certain psychotropics, such as amfebutamone (bupropion), may have few adverse sexual effects. Reversal of the dopaminergic effects of antipsychotics or the serotonergic effects of antidepressants are other strategies that may be useful. Finally, there is good evidence that adrenergic receptors mediate erection and ejaculation. As a result, there is increasing research on the efficacy of agents such as yohimbine, an α2-noradrenergic antagonist, for the treatment of sexual adverse effects",
author = "Stein, {Dan J.} and Eric Hollander",
year = "1994",
doi = "10.2165/00023210-199402010-00006",
language = "English (US)",
volume = "2",
pages = "78--86",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Sexual Dysfunction Associated with the Drug Treatment of Psychiatric Disorders

T2 - Incidence and Treatment

AU - Stein, Dan J.

AU - Hollander, Eric

PY - 1994

Y1 - 1994

N2 - Adverse sexual effects of psychiatric medication can cause considerable distress to patients and so lead to noncompliance. Despite the clinical importance of psychotropic-induced sexual dysfunction, there is relatively little systematic research on its incidence and treatment. Investigation is complicated by the fact that sexual dysfunction may predate the onset of medication or may be secondary to the presenting illness. In addition, objective measures of sexual dysfunction have been difficult to construct. Few studies have attempted to combine phenomenological and physiological measures of sexual dysfunction. Nevertheless, studies suggest that sexual dysfunction is commonly seen in association with the major classes of psychotropic medication. Disturbances of erection and ejaculation are the most frequently reported sexual adverse effects of dopamine blocking antipsychotics. Antidepressant medications often lead to sexual dysfunction, with serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors commonly resulting in anorgasmia. On the other hand, certain serotonergic agents (e.g. 5-HT1A agonists) may lead to improvement in sexual symptoms, pointing to the complexity of serotonergic mediation of sexual function. Treatment of sexual dysfunction induced by psychiatric drugs commonly involves attempting to titrate dosage, or switching from one medication to another. Certain psychotropics, such as amfebutamone (bupropion), may have few adverse sexual effects. Reversal of the dopaminergic effects of antipsychotics or the serotonergic effects of antidepressants are other strategies that may be useful. Finally, there is good evidence that adrenergic receptors mediate erection and ejaculation. As a result, there is increasing research on the efficacy of agents such as yohimbine, an α2-noradrenergic antagonist, for the treatment of sexual adverse effects

AB - Adverse sexual effects of psychiatric medication can cause considerable distress to patients and so lead to noncompliance. Despite the clinical importance of psychotropic-induced sexual dysfunction, there is relatively little systematic research on its incidence and treatment. Investigation is complicated by the fact that sexual dysfunction may predate the onset of medication or may be secondary to the presenting illness. In addition, objective measures of sexual dysfunction have been difficult to construct. Few studies have attempted to combine phenomenological and physiological measures of sexual dysfunction. Nevertheless, studies suggest that sexual dysfunction is commonly seen in association with the major classes of psychotropic medication. Disturbances of erection and ejaculation are the most frequently reported sexual adverse effects of dopamine blocking antipsychotics. Antidepressant medications often lead to sexual dysfunction, with serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors commonly resulting in anorgasmia. On the other hand, certain serotonergic agents (e.g. 5-HT1A agonists) may lead to improvement in sexual symptoms, pointing to the complexity of serotonergic mediation of sexual function. Treatment of sexual dysfunction induced by psychiatric drugs commonly involves attempting to titrate dosage, or switching from one medication to another. Certain psychotropics, such as amfebutamone (bupropion), may have few adverse sexual effects. Reversal of the dopaminergic effects of antipsychotics or the serotonergic effects of antidepressants are other strategies that may be useful. Finally, there is good evidence that adrenergic receptors mediate erection and ejaculation. As a result, there is increasing research on the efficacy of agents such as yohimbine, an α2-noradrenergic antagonist, for the treatment of sexual adverse effects

UR - http://www.scopus.com/inward/record.url?scp=0003322726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0003322726&partnerID=8YFLogxK

U2 - 10.2165/00023210-199402010-00006

DO - 10.2165/00023210-199402010-00006

M3 - Article

VL - 2

SP - 78

EP - 86

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 1

ER -